Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)-based preoperative systemic therapy experienced no extra clinical benefits with postoperative regional nodal irradiation (RNI).
Major finding: Patients who did vs did not receive RNI had comparable locoregional recurrence frequency (2.6% vs 1.0%; P = .651) and disease-free survival outcomes (hazard ratio 0.72; P = .638); however, pathological complete response was achieved by a significantly higher proportion of patients in the no-RNI vs RNI group (72.5% vs 44.4%; P < .001).
Study details: This retrospective study included 255 patients with HER2+ BC who received six cycles of TCHP, of which 60% of patients received RNI.
Disclosures: This study did not declare the source of funding or conflicts of interest.
Source: Kim N, Kim J-Y, et al. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer. Breast. 2023;72:103594 (Oct 30). doi: 10.1016/j.breast.2023.103594